The role of transforming growth factor beta-1 in the progression of HIV/AIDS and development of Non-AIDS-defining fibrotic disorders

Frontiers in Immunology

Volumn 8, Issue NOV, 2017, Pages

  Theron, Annette J ^a,b   Anderson, Ronald ^a   Rossouw, Theresa M ^a   Steel, Helen C ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

Highly active antiretroviral therapy; Immunosuppression; Lymphoid fibrosis; Macrophages; Non AIDS defining disorders; Organ fibrosis; T regulatory cells; Transforming growth factor beta

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ANTIINFLAMMATORY ACTIVITY; CARDIOTOXICITY; DISEASE COURSE; FIBROSIS; HEART DISEASE; HEART MUSCLE FIBROSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; KIDNEY FIBROSIS; LIVER FIBROSIS; LIVER TOXICITY; LUNG FIBROSIS; LUNG TOXICITY; MACROPHAGE; MENTAL CAPACITY; NEPHROTOXICITY; OXIDATIVE STRESS; REGULATORY T LYMPHOCYTE; REVIEW; TARGET CELL;

EID: 85032719215     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01461     Document Type: Review

References (188)

1. De Boer RJ. Time scales of CD4+ T cell depletion in HIV infection. PLoS Med (2007) 4:e193. doi:10.1371/journal.pmed.0040193
2. Zeng M, Southern PJ, Reilly CS, Beilman GJ, Chipman JG, Schacker TW, et al. Lymphoid tissue damage in HIV-infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog (2012) 8:e1002437. doi:10.1371/journal.ppat.1002437
3. Ipp H, Zemlin A. The paradox of the immune response in HIV infection: when inflammation becomes harmful. Clin Chim Acta (2013) 416:96-9. doi:10.1013/j.cca.2012.11.025
4. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol (2013) 21:6-13. doi:10.1016/j.tim.2012.09.001
5. Doitsh G, Greene WC. Dissecting how CD4 T cells are lost during HIV infection. Cell Host Microbe (2016) 19:280-91. doi:10.1016/j.chom.2016.02.012
6. Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J, Prokopowicz D. Increased plasma transforming growth factor-beta1 is associated with disease progression in HIV-1-infected patients. Viral Immunol (2004) 17:109-13. doi:10.1089/088282404322875502
7. Maina EK, Abana CZ, Bukusi EA, Sedegah M, Lartey M, Ampofo WK. Plasma concentrations of transforming growth factor beta 1 in non-progressive HIV-1 infection correlates with markers of disease progression. Cytokine (2016) 81:109-16. doi:10.1016/j.cyto.2016.02.006
8. Travis MA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol (2014) 32:51-82. doi:10.1146/annurev-immunol-032713-120257
9. Tsuchida Y, Sumitomo S, Ishigaki K, Suzuki A, Kochi Y, Tsuchiya H, et al. TGF-β3 inhibits antibody production by human B cells. PLoS One (2017) 12:e0169646. doi:10.1371/journal.pone.0169646
10. Zeng M, Smith AJ, Wietgrefe SW, Southern PJ, Schacker TW, Reilly CS, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest (2011) 121:998-1008. doi:10.1172/JCI45157
11. Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol (2016) 8:a021873. doi:10.1101/cshperspect.a021873
12. Blobe GC, Schiemann WP, Lodish F. Role of transforming growth factor β in human disease. N Engl J Med (2000) 342:1350-8. doi:10.1056/NEJM200005043421807
13. Prud'homme GJ, Piccirillo CA. The inhibitory effects of transforming growth factor-beta-1 (TGF-β1) in autoimmune diseases. J Autoimmun (2000) 14:23-42. doi:10.1006/jaut.1999.0339
14. Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-β. J Biochem (2010) 147:781-92. doi:10.1093/jb/mvq043
15. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature (1992) 359:693-9. doi:10.1038/359693a0
16. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A (1993) 90:770-4. doi:10.1073/pnas.90.2.770
17. Do T-V, Kubba LA, Du H, Sturgis CD, Woodruff TK. Transforming growth factor-β1, transforming growth factor-β2, and transforming growth factor-β3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res (2008) 6:695-705. doi:10.1158/1541-7786.MCR-07-0294
18. Okamura T, Morita K, Iwasaki Y, Inoue M, Komai T, Fujio K, et al. Role of TGF-β3 in the regulation of immune responses. Clin Exp Rheumatol (2015) 33:S63-9.
19. Tran DQ. TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells. J Mol Cell Biol (2012) 4:29-37. doi:10.1093/jmcb/mjr033
20. Wan YY, Flavell RA. 'Yin-Yang' functions of TGF-β and Tregs in immune regulation. Immunol Rev (2007) 220:199-213. doi:10.1111/j.1600-065X.2007.00565.x
21. Martelossi Cebinelli GC, Paiva Trugilo K, Badaró Garcia S, Brajão de Oliveira K. TGF-β1 functional polymorphisms: a review. Eur Cytokine Netw (2016) 27:81-9. doi:10.1684/ecn.2016.0382
22. Kruit A, Grutters JC, Ruven HJT, Van Moorsel CHM, Weiskirchen R, Mengsteab S, et al. Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest (2006) 129:1584-91. doi:10.1378/chest.129.6.1584
23. Arkwright PD, Laurie S, Super M, Pravica V, Schwarz J, Webb AK, et al. TGF-β1 genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax (2000) 55:459-62. doi:10.1136/thorax.55.6.459
24. Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol (2000) 165:4773-7. doi:10.4049/jimmunol.165.9.4773
25. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med (2002) 195:1499-505. doi:10.1084/jem.20012076
26. Gorham JD, Güler ML, Fenoglio D, Gubler U, Murphy KM. Low dose TGF-beta attenuates IL-12 responsiveness in murine Th cells. J Immunol (1998) 161:1664-70.
27. Wang J, Guan E, Roderiquez G, Norcross MA. Synergistic induction of apoptosis in primary CD4 (+) T cells by macrophage-tropic HIV-1 and TGF-beta1. J Immunol (2001) 167:3360-6. doi:10.4049/jimmunol.167.6.3360
28. Thomas DA, Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell (2005) 8:369-80. doi:10.1016/j.ccr.2005.10.012
29. Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, von Boehmer H, et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity (2006) 25:129-41. doi:10.1016/j.immuni.2006.04.015
30. Ouyang W, Beckett O, Ma Q, Li MO. Transforming growth factor-β signalling curbs thymic negative selection promoting regulatory T cell development. Immunity (2010) 32:642-53. doi:10.1016/j.immuni.2010.04.012
31. Chen WJ, Jin WW, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25-naïve T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med (2003) 198:1875-86. doi:10.1084/jem.20030152
32. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-β to convert naïve CD4+CD25-cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol (2007) 178:2018-27. doi:10.4049/jimmunol.178.4.2018
33. Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol (2008) 181:3784-92. doi:10.4049/jimmunol.181.6.3784
34. Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, et al. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One (2011) 6:e22842. doi:10.1371/journal.pone.0022842
35. Viel S, Marçais A, Guimaraes FS, Loftus R, Rabilloud J, Grau M, et al. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal (2016) 9:ra19. doi:10.1126/scisignal.aad1884
36. Strobl H, Knapp W. TGF-β1 regulation of dendritic cells. Microbes Infect (1999) 1:1283-90. doi:10.1016/S1286-4579(99)00256-7
37. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. The polarization of immune cells in the tumour environment by TGFβ. Nat Rev Immunol (2010) 10:554-67. doi:10.1038/nri2808
38. Seeger P, Musso T, Sozzani S. The TGF-β superfamily in dendritic cell biology. Cytokine Growth Factor Rev (2015) 26:647-57. doi:10.1016/j.cytogfr.2015.06.002
39. Yamaguchi Y, Tsumura H, Miwa M, Inaba K. Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells (1997) 15:144-53. doi:10.1002/stem.150144
40. Ito M, Minamiya Y, Kawai H, Saito S, Saito H, Nakagawa T, et al. Tumor-derived TGFβ-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol (2006) 176:5637-43. doi:10.4049/jimmunol.176.9.5637
41. Imai K, Minamiya Y, Koyota S, Ito M, Saito H, Sato Y, et al. Inhibition of dendritic cell migration by transforming growth factor-1 increases tumor-draining lymph node metastasis. J Exp Clin Cancer Res (2012) 31:3. doi:10.1186/1756-9966-31-3
42. Werner F, Jain MK, Feinberg MW, Sibinga NE, Pellacani A, Wiesel P, et al. Transforming growth factor-β1 inhibition of macrophage activation is mediated via Smad3. J Biol Chem (2000) 275:36653-8. doi:10.1074/jbc.M004536200
43. Naiki Y, Michelsen KS, Zhang W, Chen S, Doherty TM, Arditi M. Transforming growth factor-β differentially inhibits MyD88-dependent, but not TRAM-and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. J Biol Chem (2005) 280:5491-5. doi:10.1074/jbc.C400503200
44. Lagraoui M, Gagnon L. Enhancement of human neutrophil survival and activation by TGF-beta 1. Cell Mol Biol (1997) 43:313-8.
45. Smith WB, Noack L, Khew-Goodall Y, Isenmann S, Vadas MA, Gamble JR. Transforming growth factor-beta 1 inhibits the production of IL8 and the transmigration of neutrophils through activated endothelium. J Immunol (1996) 157:360-8.
46. Shen L, Smith JM, Shen Z, Erikkson M, Sentman C, Wira CR. Inhibition of human neutrophil degranulation by transforming growth factor-β1. Clin Exp Immunol (2007) 149:155-61. doi:10.1111/j.1365-2249.2007.03376.x
47. Allen JB, Wong HL, Guyre PM, Simon GL, Wahl SM. Association of circulating receptor FcγRIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor-β. J Clin Invest (1991) 87:1773-9. doi:10.1170/JCI115196
48. Johnson MD, Kim P, Tourtellotte W, Federspiel CF. Transforming growth factor beta and monocyte chemotactic protein-1 are elevated in cerebrospinal fluid of immunocompromised patients with HIV-1 infection. J NeuroAIDS (2004) 2:33-43. doi:10.1300/J128v02n04_03
49. Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood (2006) 108:3808-17. doi:10.1182/blood-2006-05-021576
50. Morris D, Guerra C, Donohue C, Oh H, Khurasany M, Venketaraman V. Unveiling of the mechanisms for decreased glutathione in individuals with HIV infection. Clin Dev Immunol (2012) 2012:734125. doi:10.1155/2012/734125
51. Malherbe G, Steel HC, Cassol S, de Oliveira T, Seebregts CJ, Anderson R, et al. Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection. Mediators Inflamm (2014) 2014:198413. doi:10.1155/2014/198413
52. Márquez M, Romero-Cores P, Montes-Oca M, Martin-Aspas A, Soto-Cárdenas M-J, Guerrero F, et al. Immune activation response in chronic HIV-infected patients: influence of hepatitis C virus coinfection. PLoS One (2015) 10:e0119568. doi:10.1371/journal.pone.0119568
53. Makhubele TG, Steel HC, Anderson R, van Dyk G, Theron AJ, Rossouw TM. Systemic immune activation profiles of HIV-1 subtype C-infected children and their mothers. Mediators Inflamm (2016) 2016:9026573. doi:10.1155/2016/9026573
54. Kekow J, Wachsman W, McCutchan AJ, Cronin M, Carson DA, Lotz M. Transforming growth factor β and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci U S A (1990) 87:8321-5. doi:10.1073/pnas.87.21.8321
55. Kekow J, Wachsman W, McCutchan JA, Gross WL, Zachariah M, Carson DA, et al. Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J Clin Invest (1991) 87:1010-6. doi:10.1172/JCI115059
56. Reinhold D, Wrenger S, Kähne T, Ansorge S. HIV-1 Tat: immunosuppression via TGF-β1 induction. Immunol Today (1999) 20:384-5. doi:10.1016/S0167-5699(99)01497-8
57. Hu R, Oyaizu N, Than S, Kalyanaraman VS, Wang X-P, Pahwa S. HIV-1 gp160 induces transforming growth factor-β production in human PBMC. Clin Immunol Immunopathol (1996) 80:283-9. doi:10.1006/clin.1996.0125
58. Garba ML, Pilcher CD, Bingham AL, Eron J, Frelinger JA. HIV antigens can induce TGF-β1-producing immunoregulatory CD8+ T cells. J Immunol (2002) 168:2247-54. doi:10.4049/jimmunol.168.5.2247
59. Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol (2005) 174:3143-7. doi:10.4049/jimmunol.174.6.3143
60. Epple HJ, Loddenkemper C, Kunkel D, Tröger H, Maul J, Moos V, et al. Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV-infection and normalize after suppressive HAART. Blood (2006) 108:3072-8. doi:10.1182/blood-2006-04-016923
61. Shalev I, Schmelzle M, Robson SC, Levy G. Making sense of regulatory T cell suppressive function. Semin Immunol (2011) 23:282-92. doi:10.1016/j.smim.2011.04.003
62. Paiardini M, Müller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev (2013) 254:78-101. doi:10.1111/imr.12079
63. Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection. Blood (2013) 121:29-37. doi:10.1182/blood-2012-07-409755
64. Ji J, Cloyd MW. HIV-1 binding to CD4 on CD4+CD25+ regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: an additional mechanism of suppression. Int Immunol (2009) 21:283-94. doi:10.1093/intimm/dxn146
65. Deeks SG. HIV infection, lymphoid fibrosis, and disease. Blood (2012) 120:1753-4. doi:10.1182/blood-2012-06-433987
66. Brown FD, Turley SJ. Fibroblastic reticular cells: organization and regulation of the T lymphocyte life cycle. J Immunol (2015) 194:1389-94. doi:10.4049/jimmunol.1402520
67. Liu RM, Gaston Pravia KA. Oxidative stress and glutathione in TGF-β-mediated fibrogenesis. Free Radic Biol Med (2010) 48:1-15. doi:10.1016/j.freeradbiomed.2009.09.026
68. Ly J, Lagman M, Saing T, Singh MK, Tudela EV, Morris D, et al. Liposomal glutathione supplementation restores Th1 cytokine response to Mycobacterium tuberculosis infection in HIV-infected individuals. J Interferon Cytokine Res (2015) 35:875-87. doi:10.1089/jir.2014.0210
69. Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, et al. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T cell activation following therapy. AIDS (2010) 24:1281-90. doi:10.1097/QAD.0b013e.328339e228
70. Stifano G, Affandi AJ, Mathes AL, Rice LM, Nakerakanti S, Nazari B, et al. Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis. Arthritis Res Ther (2014) 16:R136. doi:10.1186/ar4598
71. Gaardbo JC, Ronit A, Harling HJ, Gjerdrum LMR, Springborg K, Ralfkiaer E, et al. Immunoregulatory T cells may be involved in preserving CD4 T cell counts in HIV-infected long-term nonprogressors and controllers. J Acquir Immune Defic Syndr (2014) 65:10-8. doi:10.1097/QAI.0b013e3182a7c932
72. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med (2006) 145:397-406. doi:10.7326/0003-4819-145-6-200609190-00003
73. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 166:1632-41. doi:10.1001/archinte.166.15.1632
74. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 355:2283-96. doi:10.1056/NEJMoa062360
75. Wong CS, Lo FA, Cavailler P, Ng OT, Lee CC, Leo YS, et al. Causes of death in hospitalised human immunodeficiency virus (HIF)-infected patients at a national referral centre in Singapore: a retrospective review from 2008 to 2010. Ann Acad Med Singapore (2012) 41:571-6. doi:10.1111/j.1468-1293.2004.00223.x
76. Wang CJ, Silverberg MJ, Abrams DI. Non-AIDS-defining malignancies in the HIV-infected population. Curr Infect Dis Rep (2014) 16:406. doi:10.1007/s11908-014-0406-0
77. Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis (2015) 60:627-38. doi:10.1093/cid/ciu869
78. Pacheco YM, Jarrin I, Rosado I, Campins AA, Berenguer J, Iribarren JA, et al. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. Antiviral Res (2015) 117:69-74. doi:10.1016/j.antirival.2015.03.002
79. Shiels MS, Althoff KN, Pfeiffer RM, Achenbach CJ, Abraham AG, Castilho J, et al. HIV infection, immunosuppression, and age at diagnosis of non-AIDS-defining cancers. Clin Infect Dis (2017) 64:468-75. doi:10.1093/cid/ciw764
80. Langebeek N, Kooij KW, Wit FW, Stolte IG, Sprangers MAG, Reiss P, et al. Impact of co-morbidity and aging on health-related quality of life in HIV-positive and HIV-negative individuals. AIDS (2017) 31:1471-81. doi:10.1097/QAD.0000000000001511
81. Farahani M, Mulinder H, Farahani A, Marlink R. Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis. Int J STD AIDS (2017) 28:636-50. doi:10.1177/0956462416632428
82. Wester CW, Koethe JR, Shepherd BE, Stinnette SE, Rebeiro PF, Kipp AM, et al. Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. AIDS (2011) 25:1471-9. doi:10.1097/QAD.0b013e.328347f9d4
83. Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, et al. Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy. PLoS One (2016) 11:e0160460. doi:10.1371/journal.pone.0160460
84. Croxford S, Kitching A, Desai S, Kall M, Edelstein M, Skingsley A, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Public Health (2017) 2:e35-46. doi:10.1016/S2468-2667(16)30020-2
85. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 203:780-90. doi:10.1093/infdis/jiq118
86. French AL, Evans CT, Agniel DM, Cohen MH, Peters M, Landay AL, et al. Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. J Infect Dis (2013) 208:679-89. doi:10.1093/infdis/jit225
87. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis (2014) 210:1248-59. doi:10.1093/infdis/jiu254
88. So-Armah KA, Tate JP, Chang CH, Butt AA, Gerschenson M, Gibert CL, et al. Do biomarkers of inflammation, monocyte activation, and altered coagulation explain excess mortality between HIV infected and uninfected people? J Acquir Immune Defic Syndr (2016) 72:206-13. doi:10.1097/QAI.0000000000000954
89. Borges áH, O'Connor JL, Phillips AN, Neaton JD, Grund B, Neuhaus J, et al. Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-reactive protein or D-dimer during HIV infection. J Infect Dis (2016) 214:408-16. doi:10.1093/infdis/jiw173
90. Sunil M, Nigalye M, Somasunderam A, Martinez ML, Yu X, Arduino RC, et al. Unchanged levels of soluble CD14 and IL-6 over time predict serious non-AIDS events in HIV-1-infected people. AIDS Res Hum Retroviruses (2016) 32:1205-9. doi:10.1089/AID.2016.0007
91. Imp BM, Rubin LH, Tien PC, Plankey MW, Golub ET, French AL, et al. Monocyte activation is associated with worse cognitive performance in HIV-infected women with virologic suppression. J Infect Dis (2017) 215:114-21. doi:10.1093/infdis/jiw506
92. Fitzpatrick ME, Nouraie M, Gingo MR, Camp D, Kessinger CJ, Sincebaugh JB, et al. Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons. AIDS (2016) 30:1327-39. doi:10.1097/QAD.0000000000001092
93. Knudsen TB, Ertner G, Petersen J, Møller HJ, Moestrup SK, Eugen-Olsen J, et al. Plasma soluble CD163 level independently predicts all-cause mortality in HIV-1-infected individuals. J Infect Dis (2016) 214:1198-204. doi:10.1093/infdis/jiw263
94. Hsue PY, Tawakol A. Inflammation and fibrosis in HIV: getting to the heart of the matter. Circ Cardiovasc Imaging (2016) 9:e004427. doi:10.1161/CIRCIMAGING.116.004427
95. Debes JD, Bohjanen PR, Boonstra A. Mechanisms of accelerated liver fibrosis progression during HIV infection. J Clin Transl Hepatol (2016) 4:328-35. doi:10.14218/JCTH.2016.00034
96. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med (2011) 183:388-95. doi:10.1164/rccm.201006-0836OC
97. Naicker S, Rahmanian S, Kopp JB. HIV and chronic kidney disease. Clin Nephrol (2015) 83:32-8. doi:10.5414/CNP835032
98. Bódi I, Kimmel PL, Abraham AA, Svetkey LP, Klotman PE, Kopp JB. Renal TGF-beta in HIV-associated kidney diseases. Kidney Int (1997) 51:1568-77. doi:10.1038/ki.1997.215
99. Cohen AH, Cohen GM. Distinguished scientists lecture series. HIV-associated nephropathy. Nephron (1999) 83:111-6. doi:10.1159/000045486
100. Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol (2012) 59:1891-6. doi:10.1016/j.jacc.2012.02.024
101. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol (2013) 61:511-23. doi:10.1016/j.jacc.2012.06.063
102. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med (2013) 173:614-22. doi:10.1001/jamainternmed.2013.3728
103. Calza L. HIV infection and myocardial infarction. Curr HIV Res (2016) 14:456-65. doi:10.2174/1570162X14666160803114651
104. Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, et al. Increased risk of myocardial infarction in HIV-infected individuals in North America compared to the general population. J Acquir Immune Defic Syndr (2017) 75:568-76. doi:10.1097/QAI.0000000000001450
105. Crane HM, Paramsothy P, Drozd DR, Nance RM, Delaney JA, Heckbert SR, et al. Types of myocardial infarction among human immunodeficiency virus-infected individuals in the United States. JAMA Cardiol (2017) 2:260-7. doi:10.1001/jamacardio.2016.5139
106. Barnes RP, Lacson JC, Bahrami H. HIV infection and risk of cardiovascular diseases beyond coronary artery disease. Curr Atheroscler Rep (2017) 19:20. doi:10.1007/s11883-017-0652-3
107. Losina E, Hyle EP, Borre ED, Linas BP, Sax PE, Weinstein MC, et al. Projecting 10-yr, 20-yr and lifetime risks of cardiovascular disease in persons living with HIV in the US. Clin Infect Dis (2017) 65:1266-71. doi:10.1093/cid/cix547
108. Osibogun O, Ogunmoroti O, Michos ED, Spatz ES, Olubajo B, Nasir K, et al. HIV/HCV coinfection and the risk of cardiovascular disease: a meta-analysis. J Viral Hepat (2017) 24:998-1004. doi:10.1111/jvh.12725
109. Tawakol A, Lo J, Zanni M, Marmarelis E, Ihenachor E, MacNabb M, et al. Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients. J Acquir Immune Defic Syndr (2014) 66:164-71. doi:10.1097/QAI.0000000000000138
110. Fiala M, Murphy T, MacDougall J, Yang W, Luque A, Iruela-Arispe L, et al. HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol (2004) 4:327-37. doi:10.1385/CT:4:4:327
111. Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, Bienstock RJ, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS (2006) 20:675-84. doi:10.1097/01.aids.0000216367.23325.58
112. Bozkurt B. Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies. Cardiovasc Toxicol (2004) 4:243-60. doi:10.1385/CT:4:3:243
113. Dubé MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD, et al. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation (2008) 118:e36-40. doi:10.1161/CIRCULATIONAHA.107.189625
114. Melzi S, Carenzi L, Cossu MV, Passerini S, Capetti A, Rizzardini G. Lipid metabolism and cardiovascular risk in HIV-1 infection and HAART: present and future problems. Cholesterol (2010) 2010:271504. doi:10.1155/2010/271504
115. Reyskens KM, Essop MF. HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system. Biochim Biophys Acta (2014) 1842:256-68. doi:10.1016/j.bbadis.2013.11.019
116. Ahamed J, Terry H, Choi ME, Laurence J. Transforming growth factor-β-mediated cardiac fibrosis: potential role in HIV and HIV/ART-linked cardiovascular disease. AIDS (2016) 30:535-42. doi:10.1097/QAD.0000000000000982
117. Zhang YE. Non-Smad pathways in TGF-β signaling. Cell Res (2009) 19:128-39. doi:10.1038/cr.2008.328
118. Nkambule BB, Davison G, Ipp H. Platelet leukocyte aggregates and markers of platelet aggregation, immune activation and disease progression in HIV infected treatment naïve asymptomatic individuals. J Thromb Thrombolysis (2015) 40:458-67. doi:10.1007/s11239-015-1212-8
119. Guzmán-Fulgencio M, Medrano J, Rallón N, Echeverria-Urabayen A, Benito JM, Restrepo C, et al. Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. J Infect (2011) 63:382-90. doi:10.1016/j.jinf.2011.08.006
120. Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One (2013) 8:e59551. doi:10.1371/journal.pone.0059551
121. Llibre JM, Hill A. Abacavir and cardiovascular disease: a critical look at the data. Antiviral Res (2016) 132:116-21. doi:10.1016/j.antiviral.2016.05.015
122. Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-β1. Mol Genet Metab (2000) 71:418-35. doi:10.1006/mgme.2000.3032
123. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: the fibroblast awakens. Circ Res (2016) 118:1021-40. doi:10.1161/CIRCRESAHA.115.306565
124. Thiara DK, Liu CY, Raman F, Mangat S, Purdy JB, Duarte HA, et al. Abnormal myocardial function is related to myocardial steatosis and diffuse myocardial fibrosis in HIV-infected adults. J Infect Dis (2015) 212:1544-51. doi:10.1093/infdis/jiv274
125. Ntusi N, O'Dwyer E, Dorrell L, Wainwright E, Piechnik S, Clutton G, et al. HIV-1-related cardiovascular disease is associated with chronic inflammation, frequent pericardial effusions, and probable myocardial edema. Circ Cardiovasc Imaging (2016) 9:e004430. doi:10.1161/CIRCIMAGING.115.004430
126. Luetkens JA, Doerner J, Schwarze-Zander C, Wasmuth JC, Boesecke C, Sprinkart AM, et al. Cardiac magnetic resonance reveals signs of subclinical myocardial inflammation in asymptomatic HIV-infected patients. Circ Cardiovasc Imaging (2016) 9:e004091. doi:10.1161/CIRCIMAGING.115.004091
127. Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Goozé L, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis (2004) 39:1199-206. doi:10.1086/424013
128. Chawla LS, Amdur RL, Shaw AD, Faselis C, Palant CE, Kimmel PL. Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. Clin J Am Soc Nephrol (2014) 9:448-56. doi:10.2215/CJN.02440213
129. Mallipattu SK, Salem F, Wyatt CM. The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. Kidney Int (2014) 86:259-65. doi:10.1038/ki.2014.44
130. Kalim S, Szczech LA, Wyatt CM. Acute kidney injury in HIV-infected patients. Semin Nephrol (2008) 28:556-62. doi:10.1016/j.semnephrol.2008.08.008
131. Nadkarni GN, Patel AA, Yacoub R, Benjo AM, Konstantinidis I, Annapureddy N, et al. The burden of dialysis-requiring acute kidney injury among hospitalized adults with HIV infection: a nationwide inpatient sample analysis. AIDS (2015) 29:1061-6. doi:10.1097/QAD.0000000000000653
132. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health (2012) 12:234. doi:10.1186/1471-2458-12-234
133. López-Hernández FJ, López-Novoa JM. Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res (2012) 347:141-54. doi:10.1007/s00441-011-1275-6
134. Schnaper HW, Jandeska S, Runyan CE, Hubchak SC, Basu RK, Curley JF, et al. TGF-β signal transduction in chronic kidney disease. Front Biosci (2009) 14:2448-65. doi:10.2741/3389
135. Vega G, Alarcón S, San Martín R. The cellular and signalling alterations conducted by TGF-β contributing to renal fibrosis. Cytokine (2016) 88:115-25. doi:10.1013/j.cyto.2016.08.019
136. Medapalli RK, He JC, Klotman PE. HIV-associated nephropathy: pathogenesis. Curr Opin Nephrol Hypertens (2011) 20:306-11. doi:10.1097/MNH.0b013e328345359a
137. Rosenberg AZ, Naicker S, Winkler CA, Kopp JB. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol (2015) 11:150-60. doi:10.1038/nrneph.2015.9
138. Wyatt CM, Klotman PE, D'Agati VD. HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol (2008) 28:513-22. doi:10.1016/j.semnephrol.2008.08.005
139. Rifkin DE, Sarnak MJ. Does inflammation fuel the fire in CKD? Am J Kidney Dis (2009) 53:572-5. doi:10.1053/j.ajkd.2009.01.001
140. Yamamoto T, Noble NA, Miller DE, Gold LI, Hishida A, Nagase M, et al. Increased levels of transforming growth factor-beta in HIV-associated nephropathy. Kidney Int (1999) 55:579-92. doi:10.1046/j.1523-1755.1999.00296.x
141. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A (1993) 90:1814-8. doi:10.1073/pnas.90.5.1814
142. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med (1994) 331:1286-92. doi:10.1056/NEJM199411103311907
143. Mehta T, Buzkova P, Kizer JR, Diousse L, Chonchol M, Mukamal KJ, et al. Higher plasma transforming growth factor (TGF)-β is associated with kidney disease in older community dwelling adults. BMC Nephrol (2017) 18:98. doi:10.1186/s12882-017-0509-6
144. Zauli G, Davis BR, Re MC, Visani G, Furlini G, La Placa M. Tat protein stimulates production of transforming growth factor-beta 1 by marrow macrophages: a potential mechanism for human immunodeficiency virus-1-induced hematopoietic suppression. Blood (1992) 80:3036-43.
145. Shukla RR, Kumar A, Kimmel PL. Transforming growth factor beta increases the expression of HIV-1 gene in transfected human mesangial cells. Kidney Int (1993) 44:1022-9. doi:10.1038/ki.1993.344
146. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension (1998) 31:181-8. doi:10.1161/01.HYP.31.1.181
147. Qiao YC, Chen YL, Pan YH, Ling W, Tian F, Zhang XX, et al. Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: a PRISMA-compliant systematic review and meta-analysis. Medicine (2017) 96:e6583. doi:10.1097/MD.0000000000006583
148. Meyrier A, Hill GS, Simon P. Ischemic renal diseases: new insights into old entities. Kidney Int (1998) 54:2-13. doi:10.1046/j.1523-1755.1998.00968.x
149. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov (2003) 2:812-22. doi:10.1038/nrd1201
150. Cooper RD, Tonelli M. Renal disease associated with antiretroviral therapy in the treatment of HIV. Nephron Clin Pract (2011) 118:c262-8. doi:10.1159/000321646
151. Bartoli E. Adverse effects of drugs on the kidney. Eur J Intern Med (2016) 28:1-8. doi:10.1016/j.ejim.2015.12.0001
152. Sacchi P, Cima S, Corbella M, Comolli G, Chiesa A, Baldanti F, et al. Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection. Dig Liver Dis (2015) 47:218-25. doi:10.1016/j.dld.2014.11.012
153. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 6:425-56. doi:10.1146/annurev-pathol-011110-130246
154. Kawada N. Evolution of hepatic fibrosis research. Hepatol Res (2011) 41:199-208. doi:10.1111/j.1872-034X.2011.00776.x
155. Puoti M, Bonacini M, Spinetti A, Putzola V, Govindarajan S, Zaltron S, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis (2001) 183:134-7. doi:10.1086/317644
156. Gupta D, Rani M, Khan N, Jameel S. HIV-1 infected peripheral blood mononuclear cells modulate the fibrogenic activity of hepatic stellate cells through secreted TGF-β and JNK signaling. PLoS One (2014) 9:e91569. doi:10.1371/journal.pone.0091569
157. Mastroianni CM, Lichtner M, Mascia C, Zuccalà P, Vullo V. Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci (2014) 15:9184-208. doi:10.3390/ijms15069184
158. Friedman SL. Hepatic fibrosis-overview. Toxicology (2008) 254:120-9. doi:10.1016/j.tox.2008.06.013
159. Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res (2005) 29:121S-31S. doi:10.1097/01.alc.0000189284.98684.22
160. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS (2007) 21:1073-89. doi:10.1097/QAD.0b013e3281084e4d
161. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT, HIV Outpatient Study (HOPS) Investigators. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat (2010) 17:879-86. doi:10.1111/j.1365-2893.2009.01249.x
162. King J, Hagemeister DT. Hepatitis B co-infection in HIV-infected patients receiving antiretroviral therapy at the TC Newman Anti Retroviral Treatment Clinic in Paarl, Western Cape. S Afr J HIV Med (2016) 17:a336. doi:10.4102/sajhivmed.v17i1.336
163. Blackard JT, Kang M, Sherman KE, Koziel MJ, Peters MG, Chung RT. Effects of HCV treatment on cytokine expression during HCV/HIV coinfection. J Interferon Cytokine Res (2006) 26:834-8. doi:10.1089/jir.2006.26.834
164. Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim K-A, et al. HIV increases HCV replication in a TGF-β1-dependent manner. Gastroenterology (2008) 134:803-11. doi:10.1053/j.gastro.2008.01.005
165. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology (2010) 52:1143-55. doi:10.1002/hep.23716
166. Rockstroh JK, Mohr R, Behrens G, Spengler U. Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play? Curr Opin HIV AIDS (2014) 9:365-70. doi:10.1097/COH.0000000000000064
167. Sonderup MW, Wainwright HC. Human immunodeficiency virus infection, antiretroviral therapy, and liver pathology. Gastroenterol Clin North Am (2017) 46:327-43. doi:10.1016/j.gtc.2017.01.007
168. Pedersen KK, Pedersen M, Trøseid M, Gaardbo JC, Lund TT, Thomsen C, et al. Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance and risk of myocardial infarction. J Acquir Immune Defic Syndr (2013) 64:425-33. doi:10.1097/QAI.0b013e312829f919d
169. Sherman KE, Thomas D, Chung RT. Human immunodeficiency virus and liver disease forum 2012. Hepatology (2014) 59:307-17. doi:10.1002/hep.26638
170. Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev (2013) 26:2-18. doi:10.1128/CMR.00050-12
171. Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis (2012) 25:10-6. doi:10.1097/QCO.0b013e.0834ef599
172. Rohrbach J, Robinson N, Harcourt G, Hammond E, Gaudieri S, Gorgievski M, et al. Cellular immune responses to HCV core increase the HCV RNA levels decrease during successful antiretroviral therapy. Gut (2010) 59:1252-8. doi:10.1136/gut.2009.205971
173. Anderson JP, Tchetgen Tchetgen EJ, Lo Re V III, Tate JP, Williams PL, Seage GR III, et al. Antiretroviral therapy reduces the rate of hepatic decompensation among HIV-and hepatitis C virus-coinfected veterans. Clin Infect Dis (2014) 58:719-27. doi:10.1093/cid/cit779
174. Triplette M, Crothers K, Attia EF. Non-infectious pulmonary diseases and HIV. Curr HIV/AIDS Rep (2016) 13:140-8. doi:10.1007/s11904-016-0313-0
175. Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc (2011) 8:313-9. doi:10.1513/pats.201009-058WR
176. Rossouw TM, Anderson R, Feldman C. Impact of HIV infection and smoking on lung immunity and related disorders. Eur Respir J (2015) 46:1781-95. doi:10.1183/13993003.00353-2015
177. Scourfield AT, Doffman SR, Miller RF. Chronic obstructive pulmonary disease in patients with HIV: an emerging problem. Br J Hosp Med (2014) 75:678-84. doi:10.12968/hmed.2014.75.12.678
178. Ghadaki B, Kronfli N, Vanniyasingam T, Haider S. Chronic obstructive pulmonary disease and HIV: are we appropriately screening? AIDS Care (2016) 28:1338-43. doi:10.1080/09540121.2016.1189499
179. Yang YC, Zhang N, Van Crombruggen K, Hu GH, Hong SL, Bachert C. Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy (2012) 67:1193-202. doi:10.1111/j.1398-9995.2012.02880.x
180. Chiang CH, Chuang CH, Liu SL. Transforming growth factor-β1 and tumor necrosis factor-α are associated with clinical severity and airflow limitation of COPD in an additive manner. Lung (2014) 192:95-102. doi:10.1007/s00408-013-9520-2
181. Aschner Y, Downey GP. Transforming growth factor-β: master regulator of the respiratory system in health and disease. Am J Respir Cell Mol Biol (2016) 54:647-55. doi:10.1165/rcmb.2015-0391TR
182. Leader JK, Crothers K, Huang L, King MA, Morris A, Thompson BW, et al. Risk factors associated with quantitative evidence of lung emphysema and fibrosis in an HIV-infected cohort. J Acquir Immune Defic Syndr (2016) 71:420-7. doi:10.1097/QAI.0000000000000894
183. Twigg HL III, Spain BA, Soliman DM, Bowen LK, Heidler KM, Wilkes DS. Impaired IgG production in the lungs of HIV-infected individuals. Cell Immunol (1996) 170:127-33. doi:10.1006/cimm.1996.0142
184. Meng X-M, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol (2016) 12:325-38. doi:10.1038/nrneph.2016.48
185. Akhurst RJ, Hata A. Targeting the TGFβ signaling pathway in disease. Nat Rev Drug Discov (2012) 11:790-811. doi:10.1038/nrd3810
186. Woodcock HV, Maher TM. The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep (2014) 6:16. doi:10.12703/P6-16
187. George PM, Wells AU. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Rev Clin Pharmacol (2017) 10:483-91. doi:10.1080/17512433.2017
188. Estes JD, Reilly C, Trubey CM, Fletcher CV, Cory TJ, Piatak M, et al. Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T cell populations and improves immune reconstitution with antiretroviral therapy. J Infect Dis (2015) 211:744-54. doi:10.1093/infdis/jiu519